Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy Poster Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy Explore how QSP modeling informs T-cell engager dose selection for autoimmune diseases, balancing efficacy and…Piet van der Graaf2026 年 10 月 26 日
Certara Biotech Forum London: Building an Investor-Ready Strategy and Story Live Events Certara Biotech Forum London: Building an Investor-Ready Strategy and Story –Certara2026 年 10 月 19 日
2nd Model-Informed Drug Development Summit Conference 2nd Model-Informed Drug Development Summit –sarah Carr2026 年 10 月 13 日
From Data to Decisions: Getting More from Clinical Trial Evidence Webinar 从数据到决策:Getting More from Clinical Trial Evidence Matt Zierhut, PhD MBA2026 年 10 月 13 日
Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human On-Demand Webinar Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human Watch the webinar to learn how QSP and a model-informed target product profile guide indication,…Danielle Pillsbury2026 年 10 月 9 日
Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV Publication Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV Explore population PK modeling of dolutegravir in plasma and cerebrospinal fluid to characterize CNS penetration…Certara2026 年 10 月 5 日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma Publication Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma Explore a simultaneous population PK/PD model characterizing the dynamic relationships between belantamab mafodotin, sBCMA, and…Certara2026 年 10 月 5 日
2nd TCE for Autoimmune Disease Summit Conference 2nd TCE for Autoimmune Disease Summit –Danielle Pillsbury2026 年 10 月 5 日
How Do You Know You Have the Right Dose? Using Exposure-Response Evidence to Justify and Defend Dose Decisions Webinar How Do You Know You Have the Right Dose? Using Exposure-Response Evidence to Justify and Defend Dose Decisions Danielle Pillsbury2026 年 10 月 1 日
CODEX Clinical Outcomes Databases Hidradenitis Suppurativa (HS) Fact Sheet CODEX Clinical Outcomes Databases Hidradenitis Suppurativa (HS) Explore Certara's CODEX Hidradenitis Suppurativa database ~43 studies with key efficiency and safety endpoints (HiSCR50,…Danielle Pillsbury2026 年 9 月 25 日